GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

GeneThera, Inc. is a biotechnology company. The Company is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The Company has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The Company has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.